Drug intelligence / Profile preview

ICI-201

Development stage: Phase 1
Lead developer: Soochow University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ICI-201 is an autologous CAR-T cell therapy developed for the treatment of relapsed/refractory multiple myeloma. It works through immunologic cytotoxicity and T lymphocyte replacement mechanisms. The therapy reached Phase 1 clinical trials but was discontinued.

Targets

B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on ICI-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICI-201.

Explore the full profile